NANOBIOTIX (EPA:NANO) | WebDisclosure

Basculer en Français

10836	Companies
235277	Keywords
164215	Articles
126032	Press releases

Home
Companies
NANOBIOTIX

PRESS RELEASE

published on 03/27/2025 at 21:15, 1 year 4 months ago

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix announces first data from the completed dose escalation part of a Phase 1 study evaluating NBTXR3 (JNJ-1900) as a 2L+ therapy for patients with locally advanced NSCLC. The study shows favorable safety and injection feasibility, with promising survival data

NSCLC NANOBIOTIX NBTXR3 Phase 1 Study Dose Escalation
PRESS RELEASE

published on 03/27/2025 at 21:15, 1 year 4 months ago

Nanobiotix annonce les premières données issues de la partie escalade de dose completée d’une étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d’un CPNPC localement avancé
Nanobiotix annonce les premières données prometteuses de l'étude de phase 1 évaluant JNJ-1900 (NBTXR3) en traitement de 2L+ pour les patients atteints d'un CPNPC localement avancé

Traitement NANOBIOTIX CPNPC Phase 1 JNJ-1900
BRIEF

published on 03/20/2025 at 21:20, 1 year 4 months ago

Nanobiotix dévoile des résultats de Phase 1 au Congrès Européen sur le Cancer du Poumon

Biotechnologie NANOBIOTIX Cancer Du Poumon Phase 1 JNJ-1900
BRIEF

published on 03/20/2025 at 21:20, 1 year 4 months ago

Nanobiotix Unveils Phase 1 Results at European Lung Cancer Congress

Biotechnology NANOBIOTIX Lung Cancer Phase 1 JNJ-1900
PRESS RELEASE

published on 03/20/2025 at 21:15, 1 year 4 months ago

NANOBIOTIX annonce la présentation de données issues de deux études de phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon
Nanobiotix annonce la présentation de données de deux études de Phase 1 évaluant JNJ-1900 (NBTXR3) lors du Congrès Européen sur le Cancer du Poumon 2025

NANOBIOTIX Cancer Du Poumon JNJ-1900 Études De Phase 1 ELCC 2025
PRESS RELEASE

published on 03/20/2025 at 21:15, 1 year 4 months ago

NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Nanobiotix announces presentation of data from two Phase 1 studies evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference. Studies highlight safety, efficacy, and collaboration strategies

Collaboration NANOBIOTIX Lung Cancer JNJ-1900 Phase 1 Studies
BRIEF

published on 03/17/2025 at 21:20, 1 year 4 months ago

NANOBIOTIX Prolonge son Horizon Financier jusqu'à mi-2026

Accord De Licence NANOBIOTIX NBTXR3 Visibilité Financière Janssen
BRIEF

published on 03/17/2025 at 21:20, 1 year 4 months ago

NANOBIOTIX Extends its Financial Horizon until mid-2026

License Agreement NANOBIOTIX NBTXR3 Financial Visibility Janssen
PRESS RELEASE

published on 03/17/2025 at 21:15, 1 year 4 months ago

NANOBIOTIX renforce sa visibilité financière en amendant son accord de licence globale pour JNJ-1900 (NBTXR3) qui étend son horizon de trésorerie jusqu’à mi-2026
Nanobiotix renforce sa visibilité financière en amendant son accord de licence avec JNJ-1900 (NBTXR3), étendant son horizon de trésorerie jusqu’à mi-2026. Conférence le 18/03/2025

Trésorerie Accord De Licence NANOBIOTIX Visibilité Financière JNJ-1900
PRESS RELEASE

published on 03/17/2025 at 21:15, 1 year 4 months ago

NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Nanobiotix strengthens financial position by amending global licensing agreement for JNJ-1900 (NBTXR3), extending cash visibility to mid-2026. Details of the amendment and future potential milestone payments outlined

Financial Position Milestone Payments NANOBIOTIX JNJ-1900 Global Licensing Agreement

Accesswire

Published on 08/15/2026 at 00:50, 23 hours 22 minutes ago

Revive Therapeutics Reports Grant of Options
Published on 08/15/2026 at 00:15, 23 hours 57 minutes ago

Full Circle Lithium Announces Closing of Private Placement
Published on 08/14/2026 at 23:45, 1 day ago

AI/ML Innovations Inc. Announces Proposed Private Placement
Published on 08/14/2026 at 23:25, 1 day ago

NuRAN Wireless Closes $7.6 Million Financing
Published on 08/14/2026 at 23:00, 1 day 1 hour ago

Medicure Reports Financial Results for Quarter Ended June 30, 2026 and Schedules August 17, 2026 Conference Call

View all ACCESSWIRE

EQS Group

Published on 08/15/2026 at 15:05, 9 hours 7 minutes ago

Brook Gaming Officially Launches Sniper 2 Flagship Keyboard and Mouse Converter for Cross-Platform Console Gaming
Published on 08/15/2026 at 08:05, 16 hours 7 minutes ago

SKYWORTH Solar to Launch SolaMate Balcony Solar System on Joybuy Germany on August 15
Published on 08/14/2026 at 18:29, 1 day 5 hours ago

Designated Persons Notifications
Published on 08/14/2026 at 18:29, 1 day 5 hours ago

Designated Persons Notifications
Published on 08/14/2026 at 18:15, 1 day 5 hours ago

Fuller, Smith & Turner PLC: Transaction in own shares

Les Echos

Published on 08/13/2026 at 18:00, 2 days 6 hours ago

Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 4 days 6 hours ago

DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 4 days 6 hours ago

Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 5 days 6 hours ago

AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 5 days 6 hours ago

AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026

View all LES ECHOS COMFI WIRE